NBNatalia A. Batmanova

Natalia A. Batmanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalia A. Batmanova has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical use of multipotent mesenchymal stem cells in children after allogeneic bone marrow transplantation: the experience of the N.N. Blokhin National Medical Research Center of Oncology

    by R. R. Fatkhullin, M. V. Kiselevsky, E. B. Machneva, K. I. Kirgizov, I. O. Kostareva, D. S. Smirnova, T. Z. Aliev, M. A. Shervashidze, N. A. Batmanova, T. T. Valiev, et al.

    Introduction. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most important curative and consolidating treatment options for hematologic malignancies, immunologic diseases, and solid tumors. Nevertheless, its use may be limited due to life-threatening post-transplant complications, such as acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), and poor graft function. The standard treatment for these complications includes the administration of immunosuppressive drugs. However, their side effects and limited effectiveness necessitate the continued search for additional treatments, among which the use of mesenchymal stem cells (MSCs) may prove highly effective. Materials and methods. In this retrospective/prospective study conducted from 2021 to 2025, we enrolled 25 patients aged from 10 months to 16 years (with a median age of 11 years) with refractory aGVHD, cGVHD, and/or poor graft function after allo-HSCT. MSCs isolated from the bone marrow of allogeneic donors and cultured to passages 2–3 were administered intraosseously/intravenously or through a nasojejunal tube every 1–2 weeks. The primary endpoint was clinical response to therapy. Results. The median cell product dose was 20 (4–69) × 106 cells/kg recipient body weight. A response to MSC therapy was achieved in 15 (60.0%) out of 25 patients: in 8/9 (88.9%) patients with isolated poor graft function, in 4/6 patients who had both poor graft function and GVHD, and in 3/10 patients with isolated aGVHD/cGVHD. No adverse events associated with MSC administration were observed in any patient. Conclusion. The use of allogeneic MSCs in pediatric patients with refractory complications of allo-HSCT is a safe and potentially effective method. Our results are consistent with published data and warrant prospective randomized studies with a structured design and more precise response criteria.

  • Open Access

    Problems of therapy and search for curative options in infantile acute B-cell lymphoblastic leukemia: a clinical case

    by E. B. Machneva, K. A. Sergeenko, N. A. Batmanova, M. A. Shervashidze, T. T. Valiev, K. I. Kirgizov, S. R. Varfolomeeva

    Infantile acute B-cell lymphoblastic leukemia (B-ALL) is a rare leukemia that develops in children of the first year of life, prone to an aggressive course, a combination of unfavorable prognostic factors, frequent relapses and “switching” of tumor cell differentiation from lymphoid to myeloid. In addition, the physiological features and high vulnerability of the infant's body to the influence of unfavorable external factors cause a high frequency of severe complications of both the underlying disease and the specific treatment, which limits the possibilities of therapy and reduces the likelihood of a favorable outcome in such patients. In this regard, there is no doubt that the search for new curative options that increase the effectiveness and reduce the toxicity of therapy for B-ALL in infants is highly relevant. Given the rarity of this type of leukemia, fundamental studies of the biology of infantile leukemia, extensive clinical trials, and exchange of experience between transplant centers involved in the treatment of such patients are important for improving the effectiveness of its therapy. The clinical case presented in this article demonstrates the main problems of therapy for infantile B-ALL: the initial presence of a set of unfavorable prognostic factors (MLL gene rearrangement, lack of CD10 expression on tumor cells, age under 3 months, hyperleukocytosis, and central nervous system damage at manifestation), “switching” of the blast cell line from lymphoid to myeloid, poor response to glucocorticosteroids and development of severe complications limiting the possibilities of therapy intensification already at the stage of induction therapy, refractory course, relapse at late stages after allogeneic hematopoietic stem cell transplantation. Moreover, an individualized approach and the use of new treatment methods, including immunotherapy, cell therapy and apoptosis inducers, allowed the patient to achieve clinical and hematological remission with negative minimal residual disease a year after allogeneic hematopoietic stem cell transplantation, even after a relapse of leukemia.

  • Open Access

    Allogeneic Hematopoietic Stem Cell Transplantation for Infant Leukemia: A Single-Center Case Series and Narrative Review

    by Irina Kostareva, Kirill Kirgizov, Irina Shubina, Nara Stepanyan, Nataliya Batmanova, Timur Valiev, Mihail Kiselevsky, Svetlana Varfolomeeva

    Background/Objectives: Acute leukemias (AL) in children under 1-year-old are combined under the term “infant leukemia” and are a very rare malignancies, accounting for up to 5% of all childhood AL cases. The predominance of unfavorable clinical and laboratory characteristics leads to unsatisfactory treatment results, even with the use of modern treatment protocols. Patients/Methods: A comprehensive search through MEDLINE, PubMed, Scopus, and ScienceDirect using infant leukemia-related keywords was performed and included a final set of 52 academic articles. Our own experience included 11 patients with infant leukemia underwent allo-HSCT (allogeneic hematopoietic stem cell transplantation) at the NN Blokhin National Medical Research Center of Oncology in 2021–2023. Types of leukemia included acute myeloid leukemia, lymphoblastic leukemia, and mixed-phenotype acute leukemia. The most frequent cytogenetic aberration was KMT2A. All patients were in clinical and hematological remission, but four had positive MRD status (minimal residual disease). Donors: haploidentical—5 (45.4%), matched unrelated donor—5 (45.4%), and matched related donor—1 (9.2%). Graft manipulations: post-transplant cyclophosphamide was given to three patients with haplo-HSCT, and TCRαβ/CD19 depletion was performed in two patients. The type of immunosuppressive therapy (IST) varied based on the donor. Conditioning regimens were myeloablative. Results: Median follow-up was 23.5 months. Acute GVHD grade I–II developed in two patients (18%) and grade III–IV in three patients (27%). The overall survival rate was 54.5% (n = 6). The relapse rate after allo-HSCT was 18% (n = 2). The most common cause of treatment failure was infectious complications in the early post-transplant period (70%). Conclusions: Our center’s experience demonstrated acceptable transplant-related mortality and satisfactory relapse rates after allo-HSCT in patients with infant leukemia. The treatment of acute leukemia in infants is challenging, and optimal protocols are being developed around the world specifically for these patients. Taking into account the characteristics of this age group, the choice of chemotherapy drug doses should be carefully considered, and the indications for allo-HSCT should be balanced.

  • Open Access

    Allogeneic Hematopoietic Stem Cell Transplantation in Infant Leukemia: Vague Prospects? (Series Cases and Brief Review)

    by Irina Kostareva, Kirill Kirgizov, Irina Shubina, Nara Stepanyan, Nataliya Batmanova, Timur Valiev, Mihail Kiselevsky, Svetlana Varfolomeeva

    Background/Objectives: Acute leukemias (AL) in children under 1 year old are combined under the term "infant leukemia" and are a very rare malignancies, accounting for up to 5% of all childhood AL cases. The predominance of unfavorable clinical and laboratory characteristics leads to unsatisfactory treatment results, even with the use of modern treatment protocols. Patients /Methods: A comprehensive search through MEDLINE, PubMed, Scopus, and ScienceDirect using the infant leukemia-related keywords was performed and included a final set of 52 academic articles. Our own experience included 11 patients with infant leukemia underwent allo-HSCT (allogeneic hematopoietic stem cell transplantation) in NN Blokhin National Medical Research Center of Oncology in 2021-2023. Types of leukemia included acute myeloid leukemia, lymphoblastic leuke-mia, and mixed-phenotype acute leukemia. The most frequent cytogenetic aberration was KMT2A. All patients were in first complete remission. Donors: haploidentical – 5 (45.4%), matched related donor – 1 (9.2%), matched unrelated donor – 5 (45.4%). Graft manipulations: post-transplant cyclophosphamide was given to 2 patients with hap-lo-HSCT, and TCRαβ/CD19 depletion was performed in 3 patients. The type of immu-nosuppressive therapy (IST) varied based on the donor. Conditioning regimens were myeloablative. Results: Median follow-up was 23.5 months. Acute GVHD grade I–II developed in 2 patients (18%), and grade III–IV in 3 patients (27%). The current survival rate is 64% (n=7). The relapse rate after allo-HSCT was 9%. The most common cause of treatment failure was infectious complications in the early post-transplant period. Con-clusions: Our center's experience demonstrated acceptable transplant-related mortality and satisfactory relapse rates after allo-HSCT in patients with infant leukemia. The treatment of acute leukemia in infants is challenging and optimal protocols are being developed around the world specifically for these patients. Taking into account the characteristics of this age group, the choice of chemotherapy drug doses should be care-fully considered and the indications for allo-HSCT should be balanced.

  • Open Access

    False-Positive and False-Negative MRD Results in Children with Acute Lymphoblastic Leukemia: Navigating Between Scylla and Charybdis (Brief Review and Clinical Experience)

    by Yulia S. Korkina, Timur T. Valiev, Natalia A. Batmanova, Mikhail V. Kiselevskiy, Irina Z. Shubina, Kirill I. Kirgizov, Svetlana R. Varfolomeeva

    Background/Objectives: Acute lymphoblastic leukemia (ALL) is the most common malignant disease in children. Contemporary antitumor treatment protocols provide long-term survival rates in over 90% of patients with ALL. High effectiveness of the treatment has been achieved as a result of chemotherapy optimization, use of targeted drugs, up-to-date genetic information, and detection of minimal residual disease (MRD). Current highly sensitive methods for MRD detection have advantages and disadvantages, and the challenge is to distinguish between false-positive and false-negative tests. Methods: A comprehensive search through MEDLINE, PubMed, Scopus, and ScienceDirect using the MRD-related keywords was performed, and included a final set of 72 academic articles. Results: At present, flow cytometry for MRD detection provides the necessary sensitivity of 10−4 and allows for reliable prediction of ALL dynamics and effective therapeutic strategies. However, even multicolor flow cytometry (MFC) cannot avoid cases of false-positive or false-negative results. Highly sensitive and productive genomic methods in addition to MFC may enhance the accuracy of MRD evaluation. On the other hand, overwhelming efforts to reach the highest sensitivity of the detection methods may lead to the detection of clinically insignificant manifestations of minimal residual disease and, subsequently, to unjustified escalation of antitumor therapy. Conclusions: The necessary ground for an adequate sensitivity of the MRD detection methods could ensure the fine line between false-positive and false-negative MRD results in patients with childhood ALL to develop an appropriate therapeutic strategy.


  • Open Access

    Analysis of factors influencing the efficiency of autologous hematopoietic stem cell mobilization before apheresis in pediatric patients with malignant tumors

    by N. G. Stepanyan, K. I. Kirgizov, E. B. Machneva, T. T. Valiev, N. A. Batmanova, R. R. Fatkhullin, N. N. Zaguzina, I. V. Vasilyeva, T. Z. Aliev, I. O. Kostareva, et al.

    Introduction. Autologous hematopoietic stem cell transplantation (auto-HSCT) is an effective method of treatment a number of malignant neoplasms and severe non-malignant diseases in addition to standard treatment protocols. Auto-HSCT requires previous successful collection of autologous hematopoietic stem cells (HSC) by apheresis with preliminary mobilization. Standard mobilization schemes include the use of granulocyte colony-stimulating factor (G-CSF), however, some patients have insufficient mobilization (IM) of HSC, which creates significant obstacles to the collection of HSC. Timely detection of predictors of IM can allow to adjust its protocol, as well as individualize the HSC apheresis regimen. Aim of the study – based on the results of the analysis of mobilization and apheresis modes of autologous HSC in patients with various malignant neoplasms to identify the most significant factors causing IM of HSC for the further development of methods for optimizing the mobilization and collection modes of HSC.Materials and methods. The study included 257 patients aged from 3 to 215 months (median age – 84 [36.0; 144.0] months) with various malignant neoplasms who received treatment at the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia from 2019 to 2023. According to the treatment protocol of malignant neoplasms, all patients received high-dose polychemotherapy followed by auto-HSCT as a consolidation phase of treatment. HSC mobilization was performed in advance in order to successfully perform apheresis of autologous HSCs. The main group (the group IM, n = 64) of patients included persons who did not achieve a CD34+ cells in peripheral blood of 20 cells/μl by the day of apheresis, despite full compliance with the established mobilization protocol. The comparison group (the “sufficient mobilization” (SM) group, n = 193) consisted of patients who achieved a CD34+ cells in peripheral blood of 20 cells/μl or more by the day of apheresis. Mobilization regimens included various chemotherapeutic agents (G-CSF, cyclophosphamide in the previous chemotherapy scheme, plerixafor and its combinations), the dose of which, the duration of the regimen, as well as the dose escalation depended on the initial characteristics of both the main treatment protocol and the somatic and infectious status of the patient. In the studied patient groups, the frequency of factors potentially capable of influencing the quality of mobilization before HSC apheresis was analyzed: the tumor type and stage, the number of previous courses of polychemotherapy, the presence and amount of myelotoxic agents in polychemotherapy, recovery of hematopoiesis before the start of mobilization, pretreatment, response to therapy, history of radiation therapy and surgery, the need for escalation of the G-CSF dose in the mobilization mode.Results. Significant differences (p < 0.05) between the comparison groups were obtained for such factors influencing the success of mobilization as the main diagnosis (the worst mobilization results were in patients with Ewingʼs sarcoma), tumor stage and response to previous treatment (mobilization was more successful in patients with disease stabilization). A significant negative impact on the efficiency of mobilization was also demonstrated by such factors as the lack of hematopoiesis recovery before mobilization, pretreatment (4 or more courses of chemotherapy preceding mobilization), the presence of radiation therapy, a combination of radiation and surgical treatment in the therapy protocol preceding mobilization, the presence of carboplatin and temozolomide in the chemotherapy course, as well as three myelotoxic agents simultaneously, and escalation of the G-CSF dose during mobilization. Despite the worse characteristics of the graft, as well as the technically more difficult procedure for collecting HSCs in the IM group of patients, the average number of CD34+ cells per kg was 1.5 × 106 /kg [0.7–2.7], which demonstrates the possibility of achieving a suboptimal number of stem cells in one apheresis procedure even in patients with poor mobilization. However, in the group of IM, not only escalation of doses of stimulant agents, but also prolongation of the apheresis procedure itself with an increase a number of processed blood volume and the volume of the graft. This not only increases the resources spent on the procedure, but also increases the risks for patients and creates additional difficulties for specialists performing the procedure. To optimize the mobilization and collection modes of the HSC, it is necessary to take into account the presence of risk factors for poor mobilization and plan in advance for such patients an individual regimen of both escalation and monitoring of the mobilization, as well as preparation for a special regimen of HSC collection.Conclusion. According to the results of our study, significant predictors of IM are the characteristics of the main diagnosis, not an achievement of tumor regress, lack of hematopoiesis recovery before the start of mobilization, pretreatment, the presence of radiation therapy in the treatment protocol preceding mobilization, a combination of radiation and surgical treatment, the presence of carboplatin and temozolomide in the chemotherapy scheme, as well as three myelotoxic agents simultaneously, and escalation of the G-CSF dose in the mobilization mode. It is the patients who may require optimization of the mobilization and collection of HSCs.

  • Open Access

    Blueberry Muffin Baby Syndrome in a Patient with Congenital Leukemia: Clinical Case

    by Timur Z. Aliev, Tatiana S. Belysheva, Elena B. Machneva, Timur T. Valiev, Natalia A. Batmanova, Irina O. Kostareva, Tatiana I. Potemkina, Karina A. Sergeenko, Lyudmila M. Kudaeva, Irina Yu. Trushkova, et al.

    Background. Blueberry muffin baby syndrome in newborns is characterized by diffuse nodular skin lesions and it is difficult for diagnosis due to diverse etiology. Etiological factors include congenital infections, intrauterine hemolytic disease, multifocal vascular abnormalities, and neoplastic conditions. Congenital neonatal leukemia is rare disease and it is usually revealed during the first month of life. Clinical case description. This clinical case presents a patient with congenital acute myeloid leukemia and severe skin manifestations. Treatment has included risk-adapted chemotherapy with subsequent allogeneic hematopoietic stem cell transplantation from a haploidentical donor (father). Conclusion. The significance of multidisciplinary approach in management of patients with congenital leukemias consist of timely determination of the disease variant, prognostic risk group, and initiation of programmed treatment.


  • Open Access

    Treatment of children with relapsed and refractory classical Hodgkin’s lymphoma: the experience of two centers

    by N. S. Tsaplina, A. V. Kozlov, T. T. Valiev, N. A. Batmanova, I. V. Kazantsev, K. I. Kirgizov, L. S. Zubarovskaya, S. R. Varfolomeeva

    Relevance. Relapses and refractory course (r/r) develop in 10 % of children and adolescents with a newly diagnosed classical Hodgkin lymphoma (cHL). The basis for successful treatment of r/r cHL is morpho-immunohistochemical diagnostics and positron emission tomography, as well as the inclusion of targeted and immune drugs in the treatment regimen. Russian experience of intercenter interaction in the treatment of r/r cHL is small, so each new study is significant from a scientific and practical standpoint.The aim of the study is to present long-term results of r/r cHL treatment using targeted drugs, chemotherapy and autologous hematopoietic stem cell transplantation.Materials and methods. From 2003 to 2023, 73 patients with r/r cHL were included in the study. The age of the patients ranged from 5.5 to 18.6 years (median – 14.5 years). Second-line therapy was carried out according to the following regimens: ICE (n = 23; 31.5 %), ViGePP (n = 15; 20.5 %), DHAP (n = 6; 8.2 %), IEP/ABVD (n = 6; 8.2 %); 7 (9.6 %) patients underwent a change in treatment regimen due to a poor response to the first 2 courses of therapy. Sixteen (21.9 %) patients were treated according to the ViGePP regimen with the addition of brentuximab vedotin (6 injections).Results. The 10-year overall survival of patients was 76 ± 6 %, relapse-free survival (RFS) was 64 ± 6 %. When brentuximab vedotin was included in the therapy program, the RFS was higher – 83 ± 15.2 % (p = 0.09).Conclusion. The results of a joint cooperative study of two Russian clinics for the treatment of r/r cHL are presented. The data obtained allow us to state the high efficiency of second-line therapy regimens with brentuximab vedotin and subsequent autologous stem cell transplantation.


  • Open Access

    Successful treatment of acute promyelocytic leukemia with initial hyperleukocytosis, differentiated syndrome and massive intracranial hemorrhage in a child

    by S. V. Goryacheva, N. A. Batmanova, T. T. Valiev, N. V. Matinyan, A. L. Kashanina, D. S. Smirnova

    Introduction. The development of hemorrhagic syndrome at the onset of the disease in patients with acute promyelocytic leukemia (APL) is one of the main causes of therapy failures and the most common cause of death in the early stages of remission induction. The risk of severe hemorrhagic complications increases in patients with the microgranular APL variant, often accompanied with hyperleukocytosis.Aim — to present a clinical case of successful diagnosis and treatment of primary APL with initial hyperleukocytosis in a patient with massive intracranial hemorrhage and differentiated syndrome.Main findings. A clinical observation of the diagnosis and treatment of APL in a 13-year-old patient with initial hyperleukocytosis, massive intracranial hemorrhage and differentiation syndrome is presented. Data on the variable manifestations of hemorrhagic syndrome in patients with APL and its effect on survival outcomes are also given. Diagnostic criteria and approaches in the treatment of differentiation syndrome are presented on the example of a clinical observation, when early clinical diagnosis and timely initiation of special antitumor treatment in the intensive care unit made it possible to achieve clinical, hematological and molecular remission, avoiding the fatal consequences of massive intracranial hemorrhage.

  • SAFETY AND EFFECTIVENESS ASSESSMENT OF THE HEMATOPOIETIC STEM CELL MOBILIZATION AND COLLECTION METHOD IN CHILDREN FROM DIFFERENT AGE GROUPS WITH MALIGNANT NEOPLASMS. A SINGLE-CENTER EXPERIENCE

    by N.G. Stepanyan, K.I. Kirgizov, E.B. Machneva, R.R. Fatkhullin, T.Z. Aliev, I.O. Kostareva, A.P. Kazantsev, N.V. Matinyan, V.V. Zhogov, M.V. Rubanskaya, et al.